Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an
important therapeutic target in tumour cells. Agents that bind to microtubules have been part …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and …

Cytotoxic nucleoside analogues and nucleobases were among the first chemotherapeutic
agents to be introduced for the medical treatment of cancer. This family of compounds has …

Background High-dose chemotherapy with autologous stem-cell transplantation is a standard
treatment for young patients with multiple myeloma. Residual disease is almost always …

Purpose To investigate the prognostic and predictive significance of subtyping node-positive
early breast cancer by immunohistochemistry in a clinical trial of a docetaxel-containing …

Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …

Acquired genomic aberrations have been shown to significantly impact survival in several
hematologic malignancies. We analyzed the prognostic value of the most frequent …

Purpose: To analyze the available data concerning mechanisms of action of and mechanisms
of resistance to the antitubulin agents, vinca alkaloids and taxanes, and more recently …

Mucosa-associated lymphoid tissue–derived lymphoma (MALT lymphoma) is usually a very
indolent lymphoma, described as localized at diagnosis and remaining localized for a …

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …